Predictive value of Diffusion weighted MRI in patients with HNSCC treated by (chemo)radiotherapy (PREDICT study)

*Predictive value of Diffusion weighted MRI in patients with HNSCC treated by (chemo)radiotherapy (PREDICT study)* - PREDICT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON56355

Enrollment

120

Registered

2016-08-03

Start date

2016-12-29

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck squamous cell carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Squamous cell carcinoma -T2, T3 or T4 oral cavity or pharynx -T3 or T4 larynx -Technically resectable -Scheduled for primary (chemo)radiation with curative intent -*Informed consent* signed by patient

Exclusion criteria

Exclusion criteria: -Age

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the predictive value of DW-MRI and ctDNA after the start of radiotherapy based on a single scan during treatment.	—

Secondary

Measure	Time frame
ADC level and tumor volume pretreatment; Change in ADC levels, ctDNA and gross tumor volume prior to, during and after therapy; The optimal time point for MRI scanning during treatment in order to predict treatment outcome.	—

Countries

Netherlands

Outcome results